Literature DB >> 2595657

An evaluation of impedance plethysmography and 125I-fibrinogen leg scanning in patients following hip surgery.

M K Cruickshank1, M N Levine, J Hirsh, A G Turpie, P Powers, R Jay, M Gent.   

Abstract

Venous thromboembolism is a common post-operative complication in patients following hip surgery. 125I-fibrinogen leg scanning and impedance plethysmography (IPG), are often used in the detection of venous thrombi in such patients. Information on the sensitivity and specificity of these non-invasive tests for the diagnosis of venous thrombosis following hip surgery is relevant for both patient management and for choosing the appropriate outcome measure for clinical trials evaluating new prophylactic regimens. We determined the sensitivity and specificity of the IPG alone, the 125I-fibrinogen leg scan alone, as well as the combined use of the two tests from a retrospective analysis of 685 hip surgery patients who participated in clinical trials of anti-thrombotic prophylaxis. These patients were followed prospectively with non-invasive tests. Bilateral venography was attempted either when one or both screening tests became positive or on day 10-14 post-operatively if both screening tests remained negative. Adequate venography was obtained in 1,010 (73.7%) legs and thrombi were identified in 198 (19.6%) legs. The sensitivities of the IPG and leg scanning were 12.9% and 44.6% respectively; the corresponding specificities were 98.1% and 95.0%. The sensitivity of a positive result on one or both screening tests was 49.6% with a specificity of 93.9%. Therefore, leg scanning and IPG, even in combination, are not sufficiently accurate to be recommended as the only strategy for the diagnosis of venous thrombosis following hip surgery. Venography should be considered in all patients undergoing surveillance testing either when one or both of the screening tests become positive or on day 10-14 if the screening tests remain negative.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2595657

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

Review 1.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

Review 2.  The risk of thromboembolism in patients undergoing colorectal surgery.

Authors:  R S McLeod
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 3.  Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism.

Authors:  D R Anderson; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

4.  DVT prophylaxis in total hip replacement.

Authors:  T G DeLoughery
Journal:  J Gen Intern Med       Date:  1993-11       Impact factor: 5.128

5.  Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: a preliminary report.

Authors:  J A Klem; J V Schaffer; P D Crane; J A Barrett; G A Henry; L Canestri; M D Ezekowitz
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

Review 6.  A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.

Authors:  Sam Schulman; Ammar Majeed
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

Review 7.  The pathogenesis and prevention of thromboembolic complications in patients undergoing total hip replacement.

Authors:  D K Potyk; H J Tabbarah
Journal:  J Gen Intern Med       Date:  1993-04       Impact factor: 5.128

8.  IVC filters may prevent fatal pulmonary embolism in musculoskeletal tumor surgery.

Authors:  Benjamin Tuy; Chinmoy Bhate; Kathleen Beebe; Francis Patterson; Joseph Benevenia
Journal:  Clin Orthop Relat Res       Date:  2008-11-07       Impact factor: 4.176

Review 9.  Peripheral vascular disease assessment in the lower limb: a review of current and emerging non-invasive diagnostic methods.

Authors:  Elham Shabani Varaki; Gaetano D Gargiulo; Stefania Penkala; Paul P Breen
Journal:  Biomed Eng Online       Date:  2018-05-11       Impact factor: 2.819

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.